Hypha Discovery is a microbial technology company helping partners in pharmaceutical and agrochemical R&D succeed through the discovery and production of microbial and mammalian metabolites. We are experts in the scalable production of DMPK metabolites and generation of polar analogues, and are also a leading provider of unique natural product screening libraries and associated services.
NEWS & EVENTS
Drug Discovery Chemistry, 19th-21st April, Hilton San Diego Resort & Spa, San Diego, CA
27th Symposium on Medicinal Chemistry in Eastern England, 21st April, Hatfield, UK
Other events you can see us at:
252nd ACS National Meeting & Exposition, 21st-25th August, Philadelphia, PA, visit us at Booth #536
Hypha present a joint poster with Incyte at the Drug Discovery Chemistry in San Diego. The poster titled “Biocatalytic C-H Activation of the JAK Inhibitor Ruxolitinib” describes how Hypha’s microbial-based biocatalytic technology was applied to produce an array of hydroxylated and further oxidised keto metabolites of first-in-class JAK inhibitor ruxolitinib. Download a copy here